Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Eye camera spots hidden inflammation in MS patients

NCT ID NCT04289909

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study used a special eye camera (adaptive optics) to look at blood vessel inflammation in the retina of 50 people with multiple sclerosis (MS) and healthy volunteers. The goal was to see if this inflammation differs between MS types and could serve as an early marker of disease activity. Researchers measured the width of inflammation around retinal vessels, comparing MS patients to controls.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a new way to monitor MS activity and progression by looking at the eye, without invasive tests.
What could go wrong
This is a small, completed observational study with only 50 participants. It does not test a treatment, so it may not directly change patient care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

50 people

The number who actually took part.

Started

Dec 2020

Finished

Jul 2024

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Group 1: * Age between 18 and 60 years old. * Relapsing remitting MS (criteria of McDonald 2017) * Less than 10 years of disease duration * Subject who has never presented a clinical episode of optic neuritis * Affiliation to a social security scheme or beneficiary of such a scheme Group 2: * Age between 18 and 60 years old * Relapsing remitting MS (criteria of McDonald 2017) * Less than 10 years of disease duration * Subject presenting an acute episode of retrobulbar optic neuritis within 3 months from onset * After optimal treatment for the retrobulbar optic neuritis * Affiliation to a social security scheme or beneficiary of such a scheme Group 3: * Age between 18 and 60 years old * Primary or Secondary progressive multiple sclerosis within 10 years of progressive phase; * Affiliation to a social security scheme or beneficiary of such a scheme Group 4 (Healthy Subjects): * Age between 18 and 60 years old * Affiliation to a social security scheme or beneficiary of such a scheme Exclusion Criteria: For all patients (Group 1; 2; 3): * Corticosteroid treatment within one month from inclusion * Other neurological, ophthalmologic or systemic disease; * Severe symptoms of uncontrolled chronic disease (renal, hepatic, hematologic, gastro-intestinal, pulmonary or cardiac or any intercurrent uncontrolled disease at inclusion) * Severe renal dysfunction (glomerular filtration rate \< 30mL/min). This non-inclusion criteria will be verified by serum creatinine test within six months from inclusion; * Contraindication for MRI; * Pregnancy or breast-feeding; * Unwillingness to be informed in case of abnormal MRI (with a significant medical anomaly) * Incapacity to understand or sign the consent form; * Adults legally protected (under judicial protection, guardianship, or supervision), persons deprived of their liberty. For healthy subjects (Group 4): * Neurological, ophthalmologic or systemic disease; * Severe symptoms of uncontrolled chronic disease (renal, hepatic, hematologic, gastro-intestinal, pulmonary or cardiac or any intercurrent uncontrolled disease at inclusion); * Contraindication for MRI; * Pregnancy or breast-feeding; * Unwillingness to be informed in case of abnormal MRI (with a significant medical anomaly) * Incapacity to understand or sign the consent form; * Adults legally protected (under judicial protection, guardianship, or supervision), persons deprived of their liberty.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Eye diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Institut du Cerveau et de la Moelle epiniere - Hopital Pitie Salpetriere

    Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.